FUNDAMENTALS · Fundamentals · KR Healthcare

Shinhung (004080) Fundamentals 2026 — P/E 37.8x, Revenue Analysis | SniperIQ

Shinhung (004080) is a KR-listed Healthcare company in Medical - Devices with a market capitalization of ₩129.9B, trading at ₩14020.00 on the KSC. This SniperIQ fundamentals page covers Shinhung's valuation (P/E 37.8x, P/B 1.2x), profitability (net margin 3.2%), revenue (₩102.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩129.9B
P/E (TTM)37.8x
Net Margin3.2%
Revenue (FY25)₩102.6B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Shinhung's market cap?

Shinhung (004080) has a market capitalization of approximately ₩129.9B, trading at ₩14020.00 on the KSC. Market cap moves with the live share price.

What is Shinhung's P/E ratio?

Shinhung's trailing twelve-month P/E ratio is 37.8x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Shinhung?

Shinhung runs a net profit margin of 3.2%, a gross margin of 30.7%, and an operating margin of 6.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Shinhung generate?

Shinhung reported revenue of ₩102.6B for fiscal year 2025, with net income of ₩2.8B and earnings per share (EPS) of 311. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Shinhung pay a dividend?

Shinhung offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Shinhung financially healthy?

Shinhung carries a debt-to-equity ratio of 0.15x and a current ratio of 1.79x, with a market beta of 0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Shinhung a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shinhung (004080) the key facts are: market cap ₩129.9B, P/E 37.8x, revenue ₩102.6B, 52-week range 13150-14760. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Shinhung's full fundamentals live

Get Shinhung's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: AstraZeneca (AZN) fundamentals · Danaher (DHR) fundamentals · Samil Pharmaceutical (000520) fundamentals · Bristol-Myers Squibb (BMY) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons